Author

Bruno G. Reigner

Observed names: B G Reigner, B REIGNER, B Reigner, B. G. Reigner, B. Reigner, B.G. Reigner, Bruno Reigner

Institutions: F. Hoffmann-La Roche AG, Roche Pharma (Schweiz) AG (Switzerland)

Observed institutions: F. Hoffmann-La Roche AG, Brooke Army Medical Center, Northwell Health, The University of Texas at San Antonio Health Science Center, University of California, San Francisco, Georgetown University, Charles University, Aberdeen Royal Infirmary, Cancer Research UK, University of California System, Roche (Japan), Christchurch Clinical Studies Trust, King's College Hospital, Roche Pharma (Schweiz) AG (Switzerland)

OpenAlex ID: A5042403751

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

2000 · Johannes Sch�ller, Jim Cassidy, et al. · Cancer Chemotherapy and Pharmacology · 660

Clinical Pharmacokinetics of Capecitabine

2001 · Bruno Reigner, Karen Blesch, et al. · Clinical Pharmacokinetics · 389

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

1998 · M Mackean, A Planting, et al. · Journal of Clinical Oncology · 263

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

1998 · D R Budman, N J Meropol, et al. · Journal of Clinical Oncology · 260

Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease

2006 · Iain C. Macdougall, Richard Robson, et al. · Clinical Journal of the American Society of Nephrology · 190

Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations

1999 · Thierry Lav??, Philippe Coassolo, et al. · Clinical Pharmacokinetics · 162

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.

1998 · B Reigner, J Verweij, et al. · PubMed · 159

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.

1999 · C Twelves, R Glynne-Jones, et al. · PubMed · 154

Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients

2002 · Christopher Poole, Jill Gardiner, et al. · Cancer Chemotherapy and Pharmacology · 134

Estimating the starting dose for entry into humans: principles and practice

2002 · Bruno G. Reigner, Karen Blesch · European Journal of Clinical Pharmacology · 130

An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development

1997 · Bruno G. Reigner, Peter E.O. Williams, et al. · Clinical Pharmacokinetics · 121

A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug

1999 · Ian R. Judson, Philip J. Beale, et al. · Investigational New Drugs · 117

Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients

2003 · Ronald Gieschke, Hans‐Ulrich Burger, et al. · British Journal of Clinical Pharmacology · 112

PDF

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

2000 · L C Pronk, P Vasey, et al. · British Journal of Cancer · 97

PDF

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

1999 · Jim Cassidy, Chris Twelves, et al. · Cancer Chemotherapy and Pharmacology · 92

A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.

1998 · J Cassidy, L Dirix, et al. · PubMed · 87

Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Cancer

2005 · Ross Camidge, Bruno Reigner, et al. · Journal of Clinical Oncology · 73

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies

1999 · Miguel A. Villalona-Calero, Geoffrey R. Weiss, et al. · Journal of Clinical Oncology · 72

Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients

1999 · Bruno Reigner, Saly Clive, et al. · Cancer Chemotherapy and Pharmacology · 70

Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience

2003 · Karen S. Blesch, Ronald Gieschke, et al. · Investigational New Drugs · 59

Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer

2003 · Bruno Reigner, Toru Watanabe, et al. · Cancer Chemotherapy and Pharmacology · 44

Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.

1997 · R Gieschke, B G Reigner, et al. · PubMed · 42

A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children

2016 · V. Lukacova, P. Goelzer, et al. · The AAPS Journal · 39

Population Pharmacokinetic Analysis of the Major Metabolites of Capecitabine

2002 · R. Gieschke, B. Reigner, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 39

Bottom‐up Meets Top‐down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children

2016 · K Jorga, C Chavanne, et al. · Clinical Pharmacology & Therapeutics · 36

Works count: 66

Citation count: 4,073

H-index: 28

I10-index: 46